Trial to Access Chelation Therapy
TACT2 follows up on the positive results of TACT, a NIH-sponsored multicenter, double-blind safety and efficacy study, which took place from 2002-2012 and was conducted in 134 sites across the United States and Canada.
TACT demonstrated an 18% reduction in recurrent heart events by chelation in patients who already had sustained a heart attack.
TACT2 will focus on diabetic patients 50 years of age or older who have survived a prior heart attack and have signs of cardiovascular disease, diabetes and toxic metals in the blood.
TACT 2 Is Looking For Participants!
Are you diabetic, over 50 and suffered a heart attack? You may be eligible to participate in a study to assess the impact of chelation therapy to reduce your future risk of heart attack, stroke or sudden death. If you or someone you know, may qualify to participate, please give us a call. We’re here to help.